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of clinical T1 renal masses, mostly due to the 
potential benefit of renal function preserva-
tion.1, 2 indeed, the volume of preserved vas-
cularized parenchyma represents a key deter-
Introduction
Partial nephrectomy (PN) is a recommended as a reference standard for the treatment 
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a B S T r a c T
iNTroDUcTioN: The definition of the safest width of healthy renal margin to achieve oncological efficacy and there-
fore of the safest resection technique (rT) during partial nephrectomy (PN) continues to be widely debated. The aim of 
this study is to evaluate the prevalence of positive surgical margins (PSM), loco-regional recurrence (lrr) and renal 
recurrence (rer) rates after simple enucleation (Se) and standard partial nephrectomy (SPN) for malignant renal tumors.
eViDeNce acQUiSiTioN: a systematic review of the english-language literature was performed through august 
2016 using the Medline, Web of Science and embase databases according to the PriSMa criteria. a systematic review 
and meta-analysis was performed in those studies that defined the exact anatomical location of recurrence after PN.
eViDeNce SYNTHeSiS: overall, 33 studies involving 11282 patients were selected for quantitative analysis. at a 
median follow-up of 43 (Se) and 52 (SPN) months, the pooled estimates of the prevalence of PSMs, lrr and rer 
were 2.7% (95% ci: 1.5-4.6%, P<0.001) and0.4% (95% ci: 0.1-2.2%, P=0.018), 2.0% (95% ci: 1.4-2.8%, P<0.001) and 
0.9% (95% ci: 0.5-1,7%, P=0.04), 1.5% (95% ci: 0.9-2.3%, P=0.001) and 0.9% (95% ci: 0.5-1,7%, P=0.40) in patients 
undergoing SPN and Se, respectively.
coNclUSioNS: our systematic analysis and meta-analysis demonstrates that Se is noninferior to SPN regarding PSM, 
lrr and rer rates in patients undergoing PN for malignant renal tumors. further studies using standardized reporting 
tools are needed to evaluate the role of resection techniques for oncologic outcomes after PN.
(Cite this article as: Minervini a, campi r, Sessa f, Derweesh i, Kaouk JH, Mari a, et al. Positive surgical margins and local 
recurrence after simple enucleation and standard partial nephrectomy for malignant renal tumors: systematic review of the 
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ence and embase databases were screened 
separately by two different authors (f.S. and 
r.c.) using two different queries in order to 
identify the articles which described the use 
of Se and SPN for the treatment of localized 
renal masses.
The first author screened all the articles in-
dexed in the aforementioned databases from 
01/01/2010 up to 18/08/2016 using the follow-
ing keywords or mesh terms: “nephron-sparing 
surgery” or “conservative nephron surgery” 
or “partial nephrectomy” or “enucleation” 
or “kidney sparing surgery” or “nephron 
sparing resection” or “enucleoresection”. 
Moreover, “nephron sparing technique” or 
“minimally invasive renal surgery” or “kid-
ney neoplasm surgery” [MeSH Major Topic] 
or “kidney diseases/surgery” [MeSH Major 
Topic] or “nephrectomy methods” [MeSH 
Major Topic] or “minimally invasive surgical 
procedures/utilization” [MeSH Major Topic]. 
The second author performed a complemen-
tary search using the same databases from 
01/01/2010 up to 18/08/2016 with the follow-
ing keywords: “partial” aND “nephrectomy” 
or “nephron-sparing surgery enucleoresec-
tion” aND “surgical margin*or recurrence 
or death or metastasis. Moreover, survival 
minant of functional recovery after surgery 
and it is strongly linked to both the tumor’s 
anatomical complexity and the PN technique 
performed.3-7
Nonetheless, the definition of the safest 
margin of healthy renal tissue that should be 
excised with the tumor and therefore of the 
oncologically safest resection technique (rT) 
during PN, has been the object of great debate 
within the urological community in the recent 
years.8 as such, the european association of 
Urology (eaU) guidelines recommendations 
changed dramatically during the last years. 
in 2010, they recommended the removal of a 
minimal tumor-free surgical margin to avoid 
local recurrence (yet without any reference to 
the specific rT), while the subsequent modifi-
cation in 2013 outlined that if the tumor was 
completely resected, the thickness of surgical 
margin (>1 mm) did not correlate with the like-
lihood of local recurrence. of note, from 2014 
they do not provide any kind of recommenda-
tion regarding the optimal margin width and/
or the most appropriate rT during PN. More-
over, the lack of a standardized nomenclature 
of different rTs undermines the interpretation 
of such recommendations.9
in this scenario, the debate about the onco-
logic safety of enucleative PN (simple enucle-
ation, Se) and the so-called standard PN (SPN) 
with a substantive parenchymal margin is still 
ongoing.8, 10
The aim of this systematic review and meta-
analysis was to evaluate the prevalence of pos-
itive surgical margins (PSM), loco-regional 
recurrence (lrr) and renal recurrence (rer) 
rates after Se and SPN in studies with a mini-
mum follow-up of 24 months.
Evidence acquisition
Search strategy
a systematic review of the literature was 
performed according to the Preferred report-
ing items for Systematic reviews and Meta-
analyses (PriSMa) criteria.11 The research 
was restricted to articles published in the 
english language. The Medline, Web of Sci-
figure 1.—literature search and study selection process 
according to the Preferred reporting items for Systematic 
reviews and Meta-analyses (PriSMa) statement criteria.
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Exclusion criteria
The current review excluded studies includ-
ing patients with solitary kidneys, genetic syn-
dromes (i.e. Von-Hippel lindau S., Birt-Hogg-
Dubè Syndrome etc.) and those articles that 
did not provide sufficient information to es-
tablish the outcome of interest for the surgical 
procedures included in this review. Moreover, 
in those studies providing accurate histologi-
cal classification of renal tumors after NSS, we 
excluded patients with benign lesions from the 
quantitative analysis. finally, whereas most re-
lapses after NSS occur within a 2-year period,2 
studies with a follow-period shorter than 24 
months were excluded from our analysis.
Data extraction
Data were extracted independently by two 
authors (f.S. and r.c.) and were subsequently 
crosschecked. a data extraction form was de-
veloped a priori in order to collect, for each 
study, relevant information on study design, 
sample size, surgical technique, pathological 
Tumor Nodes and Metastasis (TNM) stage dis-
tribution, histological type, follow-up duration 
and recurrence data within 24 months. More-
over, PSM rate and the prevalence of lrr or 
rer in patients with PSM were recorded.
Statistical analysis
for descriptive purposes, boxplots were 
generated to provide summary measures of the 
median follow-up period, pTNM stage (if de-
scribed), histologic type (clear cell renal cell 
carcinoma (rcc), papillary rcc, chromo-
phobe rcc and other subtypes) separately for 
the Se and SPN groups.
Pooled estimates were calculated, as previ-
ously described in literature,13 for the preva-
lence of lrr, rer and PSM rates within 24 
months after surgery. fixed effect model and 
DerSimonian-laird random-effects model 
were used separately for the two groups to 
provide a summary measure of the pooled-
effect estimates and corresponding 95% con-
fident intervals (ci). The DerSimonian-laird 
or oncologic outcome* enucleation” or 
“enucleative” or “enucleative” aND “partial 
nephrectomy” aND “surgical margin*” or 
“recurrence” or “death” or “metastasis” or 
“survival” or “oncologic outcome*”. in ad-
dition, both authors used the reference list of 
selected original articles and previous review 
articles on this topic for further eligible articles 
(figure 1).
The list of articles judged highly relevant 
was reviewed by all co-authors and a final ma-
jority consensus was reached on the articles 
included.
Definition of SE and SPN study groups
Studies defining the rT as the excision of 
the tumor by blunt dissection following the 
natural cleavage plane between the peritumor-
al pseudocapsule and the renal parenchyma 
without removing a visible rim of healthy re-
nal tissue 9, 12 were gathered in the Se group.
conversely, the SPN group included all 
studies defining the rT as minimal margin PN, 
standard PN, enucleoresection or not specify-
ing the amount of healthy renal tissue resected, 
as no validated definition of SPN was avail-
able in literature.9
finally, in studies including both the Se and 
SPN techniques (i.e. comparative studies), pa-
tients were grouped separately within the two 
study groups for data analysis.
Outcomes of interest
The main outcomes of interest for this re-
view were: 1) prevalence of PSM; 2) lrr rate 
and 3) renal recurrence rate (rer) after Se 
and SPN for malignant renal tumors.
loco-regional recurrence was defined ac-
cording to the eaU guidelines as recurrence 
in the ipsilateral retroperitoneum, including re-
nal parenchyma, lymph nodes or soft tissue, in 
the absence of distant metastasis.1 renal recur-
rence was defined as the presence of local re-
currence in the ipsilateral kidney, including the 
resection bed, the renal scar and the remaining 
kidney parenchyma in areas distant from the 
resection bed.
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generated by the re-execution of the research 
query in multiple databases, 1646 articles 
were finally selected for abstract evaluation. 
among these, 1565 papers were excluded due 
to inappropriate patient population (N.=589), 
use of surgical techniques different from NSS 
(N.=435), lack of information on the outcomes 
of interest for this review (N.=488) and follow-
up shorter than 24 months (N.=53). as such, 
81 papers were selected for full-text assess-
ment of eligibility. among these, 48 papers 
were excluded, including two for insufficient 
information regarding the study population, 5 
for lack of detailed description of the surgical 
technique used to perform PN, 11 for lack of 
data on the outcome of interest and 24 studies 
due to the oncological follow-up period less 
than 24 months. finally 6 studies were exclud-
ed as it was not possible to obtain the outcome 
random-effects model was used to incorporate 
in the summary measures and the between-
study variability. Heterogeneity of the preva-
lence across studies was evaluated using the 
Tau,2 an estimate of the between-study vari-
ance in the random-effects meta-analysis and 
the i2 statistic. a sensitivity analysis for rer 
was performed separately for those studies that 
defined the exact anatomical location of recur-
rence (e.g. resection bed, ipsilateral kidney or 
retroperitoneal, etc.).
all analyses were performed using r (ver-
sion 3.2.3, r Development core Team, Vien-
na, austria).
Evidence synthesis
overall, 1666 potentially relevant articles 
were detected. after removal of 20 duplicates 
Table I.—Characteristics of the studies on standard partial nephrectomy (SPN) included in our review. Numbers and 
percentages are referred to the patient population with histologically confirmed malignant renal tumors.
Study Study type Population size (N.)TNM composition (N.) Surgical technique
follow-up 
(median /mean) 
(months)
Tumor histotype (N.) PSM rate (N.,%)
recurrence rate 
in patients with 
PSM (N., %)
Masson-lecomte a, 2013 14 Prospective 49-0 T1a,47 T1b, 0 T2,2 T3, 0 T4 robotic 26 33 clear cell,13 papillary, 2 chromophobe, 6 other 3/49 (6) 0/3 (0)
Porpiglia f, 2012 15 Prospective / laparoscopic 48 / 0/41 (0) 0 (0)
Van Poppel H, 2010 16 randomized 
clinical trial
268 -105 T1,110 T2, 12 T3, 0 T4, 41 others open 112 177 clear cell papillary and chromophobe not specified 3/268 (1) /
Becker f, 2011 18 retrospective 66- 0 T1a, 5 T1b, 45 T2, 16 T3, 0 T4 open; robotic 28 51 clear cell, 9 papillary, 6 chromophobe, 25 others / /
Salami SS, 2014 29 retrospective / laparoscopic 43 7 clear cell,1 papillary, 0 chromophobe, 1 other 0/9 (0) 0 (0)
antic T, 2015 30 retrospective 406 - 299 T1a, 64 T1b, 14 T2, 29 T3, 0 T4 open; laparoscopic 33 243 clear cell, 77 papillary, 47 chromophobe, 39 others 61/406 (15) 4/61
Saito H, 2012 31 retrospective / open; laparoscopic 26 1049 clear cell,95 papillary, 36 chromophobe, 13 others 26/1193 (2) 1/26 (4)
Minervini 2011 33 retrospective 982- 727 T1a, 176 T1b, 21 T2, 21 T3, 58 others open 52 755 clear cell, 151 papillary, 59 chromophobe, 17 others 5/982 (1) /
Khalifeh a, 2013 39 retrospective 500-296 T1a, 40 T1b, 4 T2,19 T3, 0 T4, 141 others robotic; laparoscopic 24 236 clear cell,86 papillary 21 chromophobe, 157 others / /
Khalifeh a, 2013 40 retrospective 943 -763 T1a, 107 T1b, 16 T2,45 T3, 0 T4, 12 others robotic 64 607 clear cell,223 papillary, 81 chromophobe, 32 others 21/943 (2) 2/21 (10)
Jeong SJ, 2010 44 retrospective 98 -91 T1a, 4 T1b, 0 T2,2 T3, 0 T4, 1 other open; laparoscopic 71 86 clear cell, 9 papillary 3 chromophobe 3/98 (3) 0/3 (0)
Bigot P, 2014 45 retrospective 126- 0 T1a, 0 T1b, 107 T2, 19 T3, 0 T4 open; robotic; laparoscopic 30 74 clear cell, 34 papillary, 12 chromophobe, 6 others 14/126 (11) /
Mullins JK, 2012 47 retrospective 207- 168 T1a, 25 T1b,1 T2, 13 T3, 0 T4, robotic; laparoscopic 28 143 clear cell,43 papillary, 21 chromophobe, 5/207 (2) /
Zargar K, 2015 48 retrospective 505- 393 T1a, 79 T1b,16 T2, 17 T3, 0 T4, open; laparoscopic 38 362 clear cell,98 papillary, 30 chromophobe, 15 others 3/505 (1) /
ceccarelli g, 2013 51 retrospective 28- 24 T1a, 3 T1b, 0 T2, 1 T3, 0 T4, robotic 28 19 clear cell,0 papillary, 4chromophobe, 5 others 1/28 (3) /
Komninos c, 2014 52 retrospective 188- 128 T1a, 49 T1b,7 T2, 4 T3, 0 T4 robotic 43 / 10/188 (5) /
Koo Kc, 2014 53 retrospective 82- 60 T1,1 T2,21 T3, 0 T4 / 43 87 clear cell,5 papillary, 1 chromophobe, 11 others 14/104 (13) 6/14 (43)
Ha YS, 2013 54 retrospective 423 -304 T1a, 119 T1b, 0 T2, 0 T3, 0 T4 open; robotic; laparoscopic 84 423 clear cell, 0 papillary 0 chromophobe / /
Halachmi S, 2011 55 retrospective / open 55 201 clear cell, 28 papillary 0 chromophobe / /
Kreshover Je, 2013 56 retrospective 360 -302 T1a, 58 T1b, 0 T2,0 T3, 0 T4, laparoscopic 66 / 13/360 (4) 1/13 (8)
liu Z,2012 57 retrospective 168 -28 T1a, 140 T1b, 0 T2,0 T3, 0 T4, open; laparoscopic 30 154 clear cell, 14 others 1/168 (1) 0/1 /0)
Di Pierro g, 2013 58 retrospective 11- 11 T1a, 0 T1b, 0 T2,0 T3, 0 T4, laparoscopic 34 7 clear cell,3 papillary 0 chromophobe, 1 other 1/11 (9) 0/1 (0)
Dulabon lM, 2010 59 retrospective 333- 271 T1a, 42 T1b,4 T2,16 T3, 0 T4, 4 others robotic 45 222 clear cell,73 papillary 27 chromophobe, 1 other 7/333 (2) 0/7 (0)
george aK, 2014 60 retrospective / laparoscopic 42 245 clear cell,87 papillary 26 chromophobe, 88 other 6/355 (2) 0/6 (0)
Breau rH, 2010 61 retrospective 69- 0 T1a, 0 T1b, 32 T2,37 T3, 0 T4, open 38 44 clear cell,18 papillary 6 chromophobe, 1 other / /
lane, Br 2013 62 retrospective 1203-894 T1a, 227 T1b, 82 T2or higher open; laparoscopic 84 835 clear cell, 368 other types 7/1203 (1) 0/7 (0)
lane Br 2010 63 retrospective 1260- 935 T1a, 235 T1b, 90 T2or higher open; laparoscopic 54 878 clear cell, 383 other types 7/1261 (1) 0/7 (0)
roos fc, 2011 64 retrospective / open 55 39 clear cell, 19 papillary, 13 chromophobe, 2 others / /
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Table I.—Characteristics of the studies on standard partial nephrectomy (SPN) included in our review. Numbers and 
percentages are referred to the patient population with histologically confirmed malignant renal tumors.
Study Study type Population size (N.)TNM composition (N.) Surgical technique
follow-up 
(median /mean) 
(months)
Tumor histotype (N.) PSM rate (N.,%)
recurrence rate 
in patients with 
PSM (N., %)
Masson-lecomte a, 2013 14 Prospective 49-0 T1a,47 T1b, 0 T2,2 T3, 0 T4 robotic 26 33 clear cell,13 papillary, 2 chromophobe, 6 other 3/49 (6) 0/3 (0)
Porpiglia f, 2012 15 Prospective / laparoscopic 48 / 0/41 (0) 0 (0)
Van Poppel H, 2010 16 randomized 
clinical trial
268 -105 T1,110 T2, 12 T3, 0 T4, 41 others open 112 177 clear cell papillary and chromophobe not specified 3/268 (1) /
Becker f, 2011 18 retrospective 66- 0 T1a, 5 T1b, 45 T2, 16 T3, 0 T4 open; robotic 28 51 clear cell, 9 papillary, 6 chromophobe, 25 others / /
Salami SS, 2014 29 retrospective / laparoscopic 43 7 clear cell,1 papillary, 0 chromophobe, 1 other 0/9 (0) 0 (0)
antic T, 2015 30 retrospective 406 - 299 T1a, 64 T1b, 14 T2, 29 T3, 0 T4 open; laparoscopic 33 243 clear cell, 77 papillary, 47 chromophobe, 39 others 61/406 (15) 4/61
Saito H, 2012 31 retrospective / open; laparoscopic 26 1049 clear cell,95 papillary, 36 chromophobe, 13 others 26/1193 (2) 1/26 (4)
Minervini 2011 33 retrospective 982- 727 T1a, 176 T1b, 21 T2, 21 T3, 58 others open 52 755 clear cell, 151 papillary, 59 chromophobe, 17 others 5/982 (1) /
Khalifeh a, 2013 39 retrospective 500-296 T1a, 40 T1b, 4 T2,19 T3, 0 T4, 141 others robotic; laparoscopic 24 236 clear cell,86 papillary 21 chromophobe, 157 others / /
Khalifeh a, 2013 40 retrospective 943 -763 T1a, 107 T1b, 16 T2,45 T3, 0 T4, 12 others robotic 64 607 clear cell,223 papillary, 81 chromophobe, 32 others 21/943 (2) 2/21 (10)
Jeong SJ, 2010 44 retrospective 98 -91 T1a, 4 T1b, 0 T2,2 T3, 0 T4, 1 other open; laparoscopic 71 86 clear cell, 9 papillary 3 chromophobe 3/98 (3) 0/3 (0)
Bigot P, 2014 45 retrospective 126- 0 T1a, 0 T1b, 107 T2, 19 T3, 0 T4 open; robotic; laparoscopic 30 74 clear cell, 34 papillary, 12 chromophobe, 6 others 14/126 (11) /
Mullins JK, 2012 47 retrospective 207- 168 T1a, 25 T1b,1 T2, 13 T3, 0 T4, robotic; laparoscopic 28 143 clear cell,43 papillary, 21 chromophobe, 5/207 (2) /
Zargar K, 2015 48 retrospective 505- 393 T1a, 79 T1b,16 T2, 17 T3, 0 T4, open; laparoscopic 38 362 clear cell,98 papillary, 30 chromophobe, 15 others 3/505 (1) /
ceccarelli g, 2013 51 retrospective 28- 24 T1a, 3 T1b, 0 T2, 1 T3, 0 T4, robotic 28 19 clear cell,0 papillary, 4chromophobe, 5 others 1/28 (3) /
Komninos c, 2014 52 retrospective 188- 128 T1a, 49 T1b,7 T2, 4 T3, 0 T4 robotic 43 / 10/188 (5) /
Koo Kc, 2014 53 retrospective 82- 60 T1,1 T2,21 T3, 0 T4 / 43 87 clear cell,5 papillary, 1 chromophobe, 11 others 14/104 (13) 6/14 (43)
Ha YS, 2013 54 retrospective 423 -304 T1a, 119 T1b, 0 T2, 0 T3, 0 T4 open; robotic; laparoscopic 84 423 clear cell, 0 papillary 0 chromophobe / /
Halachmi S, 2011 55 retrospective / open 55 201 clear cell, 28 papillary 0 chromophobe / /
Kreshover Je, 2013 56 retrospective 360 -302 T1a, 58 T1b, 0 T2,0 T3, 0 T4, laparoscopic 66 / 13/360 (4) 1/13 (8)
liu Z,2012 57 retrospective 168 -28 T1a, 140 T1b, 0 T2,0 T3, 0 T4, open; laparoscopic 30 154 clear cell, 14 others 1/168 (1) 0/1 /0)
Di Pierro g, 2013 58 retrospective 11- 11 T1a, 0 T1b, 0 T2,0 T3, 0 T4, laparoscopic 34 7 clear cell,3 papillary 0 chromophobe, 1 other 1/11 (9) 0/1 (0)
Dulabon lM, 2010 59 retrospective 333- 271 T1a, 42 T1b,4 T2,16 T3, 0 T4, 4 others robotic 45 222 clear cell,73 papillary 27 chromophobe, 1 other 7/333 (2) 0/7 (0)
george aK, 2014 60 retrospective / laparoscopic 42 245 clear cell,87 papillary 26 chromophobe, 88 other 6/355 (2) 0/6 (0)
Breau rH, 2010 61 retrospective 69- 0 T1a, 0 T1b, 32 T2,37 T3, 0 T4, open 38 44 clear cell,18 papillary 6 chromophobe, 1 other / /
lane, Br 2013 62 retrospective 1203-894 T1a, 227 T1b, 82 T2or higher open; laparoscopic 84 835 clear cell, 368 other types 7/1203 (1) 0/7 (0)
lane Br 2010 63 retrospective 1260- 935 T1a, 235 T1b, 90 T2or higher open; laparoscopic 54 878 clear cell, 383 other types 7/1261 (1) 0/7 (0)
roos fc, 2011 64 retrospective / open 55 39 clear cell, 19 papillary, 13 chromophobe, 2 others / /
of interest separately for the different surgical 
techniques performed.
in conclusion, 33 studies were selected for 
qualitative and quantitative analysis. of note, 
only one study included both the Se and SPN 
techniques; in this case the patient cohorts 
were distributed in the two study groups for 
quantitative data analysis (Tables i, ii).14-64
Type of study and surgical technique
among the 33 studies selected for this re-
view, 29 (88%) were retrospective while 
4(12%) were prospective,14-17 of which one 
was a randomized clinical trial.16 Thirty-two 
(97%) studies provided specific information on 
the surgical approach performed during NSS. 
in most cases (20/33, 61%) an open surgical 
approach was used, either for the entire cohort 
(9/33, 27%) or combined with laparoscopic or 
robotic techniques (11/33, 83%).
Study population among the SE and SPN 
groups
overall, 11282 patients with histologically 
confirmed malignant renal tumors were in-
cluded in the analysis, of which 9861 patients 
undergoing SPN and 1421 Se. The median 
follow-up period of the studies was 52 months 
for SPN (iQr 49-58 months, range 40-58) and 
43 months for Se (interquartile range [iQr] 
31-57, range 24-112) (figure 2).
The distribution of pTNM stages was com-
parable between the Se and SPN groups (fig-
ure 3). Specifically, among the studies that spe-
cifically defined the percentages of pT stage, 
the median rate of pT1a was 74% (irQ: 55-
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range 0-54%). of note, in two studies in the 
SPN groups, the majority of patients included 
had pT2 malignant tumors.14, 18
Similarly, the median rate of each histologic 
subtype at final histopathological analysis was 
comparable, with clear cell rcc (ccrcc) 
rates of 69% (irQ: 65-78%, range 53-100%) 
81%, range 0-100%) for SPN and 70% (irQ: 
70-79%, range 51-83%) for Se, while the 
median rate of pT1b was 14% (irQ: 10-19%, 
range 0-96%) and 19% (irQ: 17-20%, range 
14-29%) for SPN and Se, respectively. The 
median rate of pT3 was 8% for SPN (irQ: 5-9 
%, range 0-20%) and 4% for Se (irQ: 1-6%, 
figure 2.—Boxplots showing the median (iQr, range) du-
ration of the follow-up period in the studies on standard 
partial nephrectomy and simple enucleation included in the 
review.
figure 3.—Boxplots showing the median (iQr, range) per-
centage of the prevalence of tumor pT stages among the 
studies on standard partial nephrectomy and simple enuclea-
tion included in the review. Percentages are referred to the 
median value of each pT stage.
Table II.—Characteristics of the studies on simple enucleation (SE) included in our review. Numbers and percent-
ages are referred to the patient population with histologically confirmed malignant renal tumors.
Study Study type Population size (N.)TNM composition (N.)
Surgical 
technique
follow-up 
(median /mean) 
(months)
Tumor histotype (N.) PSM rate (N., %)
recurrence 
rate in 
patients with 
PSM (N.,%)
Minervini a, 
2011 17
Prospective 164- 115 T1a,
31 T1b,
3 T2,
15 T3,
0 T4
open 40 114 clear cell,
27 papillary,
20 chromophobe,
3 others
0/164 (0) /
Serni S, 
2015 22
retrospective 84- 43 T1a,
24 T1b,
0 T2,
17 T3,
0 T4
open; 
robotic
54 / 3/84 (4) 1/3 (33)
Minervini a 
2011 33
retrospective 537- 422 T1a,
77 T1b,
11 T2,
27 T3,
0T4
open 52 421 clear cell,
65 papillary,
44 chromophobe,
7 others
1/537 (0,2) 0/1 (0)
Minervini a, 
2013 43
retrospective 304- 215 t1a,
60 T1b,4 T2,
25 T3,
0 T4
open 49 209 clear cell,
53 papillary,
30 chromophobe,
12 others
0/304 (0) /
Minervini a, 
2012 49
retrospective 332-275 T1a,
57 T1b,
0 T2,
0T3,
0T4
open 58 261 clear cell,
39 papillary,
27 chromophobe,
5 others
0/343 (0) /
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at the same time, Se, initially proposed as 
an alternative rT for renal preservation in pa-
tients with renal insufficiency, solitary kidneys 
or hereditary cancer syndromes, has gained 
popularity in the last ten years due to the in-
creasing evidence of its technical feasibility 
and long-term oncologic efficacy.10 indeed, 
Se has been shown to be feasible and safe 
also for highly complex renal masses, such as 
completely endophytic or hilar tumors, where 
the excision of a large safety margin of normal 
parenchyma (advocated by the SPN technique) 
might increase the risk of intraoperative com-
plications.19, 22 in addition, detailed histologi-
cal reports on Se specimens demonstrated that 
even in cases of pseudocapsule infiltration, 
the constant presence of a thin microscopic 
layer of chronic inflammatory tissue prevented 
PSMs.23 These anatomo-pathological charac-
teristics define a constant anatomic dissection 
plane (aDP) that represents a key landmark 
for surgeons during both blunt and sharp tu-
mor excisions. in this scenario, both the Se 
and minimal margin SPN strategies are hinged 
into constant anatomical features of the tumor-
parenchymal interface 8, 24 and some authors 
have even considered Se the least minimal-
margin SPN.8, 25
overall, the question as to whether the type 
of rT performed during PN (Se vs. SPN) does 
affects the rate of PSMs is still matter of dis-
cussion.10, 26
Previous reviews on this topic have reported 
an overall incidence of PSM rates after NSS 
of 0-7%.26, 27 The incidence rate was compa-
rable between open, laparoscopic and robotic 
approaches.27 Moreover, many histopathologi-
cal reports highlighted the lack of association 
between the margin size of different rTs and 
recurrence of rcc and the long-term progres-
sion-free survival.19, 28
The prevalence of PSMs after SPN in our 
review ranged from 0% to 15% (Table i). of 
note, in the retrospective study by Salami et 
al. evaluating the results of laparoscopic off-
clamp SPN in a series of 9 hilar tumors, the 
prevalence of PSMs at a median follow-up of 
43 months was 0% with no patient experienc-
ing local recurrence.29 However, the authors 
for SPN and 74% (irQ: 69-78%, range 69-
79%) for Se and papillary rcc (prcc) rates 
of 20% (irQ: 12-25%, range 0-27%) for SPN 
and 14% (irQ: 12-17%, range 12-17%) for 
Se. chromophobe rcc (crcc) was found 
in 6% (irQ: 3-9%, range 0-18%) of cases in 
the SPN group and 9% (irQ: 8-10%, range 
8-12%) in the Se group (figure 4).
Prevalence of PSMs
The goal of PN is to obtain complete exci-
sion of the tumor with negative surgical mar-
gins while preserving as much healthy renal 
parenchyma as possible. in this context, the 
rate of PSMs has traditionally been associated 
with the amount of healthy renal tissue resect-
ed with the tumor and consequently with the 
different rT performed.19 Historically, the par-
adigm of SPN firstly introduced by Vermooten 
in 1950 involved the removal of a 1 cm mar-
gin of peritumor normal renal parenchyma to 
ensure a negative surgical margin.19 However, 
the current view favors a more conservative 
resection approach toward a minimal margin 
SPN,20 as the resection of 1 cm of healthy renal 
tissue might theoretically lead to an increased 
risk of intraoperative complications and may 
reduce the amount of preservable healthy pa-
renchyma, which is key determinant of post-
operative renal functional outcomes following 
NSS.21
figure 4.—Boxplots showing the median (iQr, range) per-
centage of prevalence of each tumor histotype among the 
studies on standard partial nephrectomy and simple enuclea-
tion included in the review. Percentages are referred to the 
median value of each histopathological subtype.
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matched-pair analysis aiming to compare the 
perioperative outcomes of Se versus SPN in 
clinical T1 renal tumors in a multicenter cohort 
of patients from high-volume centers, longo 
et al. showed that the incidence of PSMs was 
significantly lower in patients treated with Se 
and 4.7 times higher in patients undergoing 
SPN.35 The same conclusions were reached by 
Schiavina et al. in a large multi-institutional 
prospective study evaluating the predictors of 
PSMs in patients undergoing PN at 19 italian 
urological centres (record Project). They 
found that PSMs rate was significantly lower 
in patients treated with Se compared to SPN 
(1.6% vs. 7.4%, respectively; P<0.0001) and 
that, on multivariable analysis, SPN, age, up-
per pole tumor location and fuhrman 3-4 
nuclear grade were independent predictors of 
PSMs.34 These findings suggest the close rela-
tionship between rT and PSMs rate after PN 
and the possible lower risks of well-performed 
Se for the achievement of negative margins.
compared to the studies on SPN, the reports 
on Se showed a less variability in PSM rate 
(range 0-4% vs. 0-15%), possibly due to both 
technical-related and methodological-related 
aspects. indeed, most series on Se were per-
formed in high-volume centers with extensive 
experience in the enucleative techniques (thus 
reducing the possibility of variable surgical 
outcomes across different surgeons and insti-
tutions), while the SPN group includes, by def-
inition, different kinds of rTs and consequent-
ly possible variations in surgical margin width 
and status. Moreover, our review could not 
discriminate the various technical refinements 
of the SPN concept and grouped all the non 
enucleative rTs into the same study category. 
as such, this might have led to a selection bias 
when analyzing the rate of PSM after SPN.
overall, our meta-analysis showed that, 
at a median follow-up of 43 and 52 months, 
the pooled estimations of the prevalence of 
PSMs in patients undergoing SPN and Se 
were 2.7% (95% ci: 1.5-4.6%, tau²=1.435, 
i2=92.4%, P<0.001) and 0.4% (95% ci: 0.1-
2.2%, tau²=2.246, i2=66.3%, P=0.018). These 
results suggested strong evidence against the 
null hypothesis of differences in the pooled 
stressed that a negative surgical margins did 
not necessarily translate into recurrence-free 
survival.29 on the contrary, in the retrospec-
tive cohort study by antic et al., PSMs were 
recorded in 61/406 (15%) patients with rcc 
after SPN, with 4/61 (7%) patients with PSMs 
experiencing local recurrence (within the ip-
silateral kidney) at a median follow-up of 33 
months. The authors concluded that the type 
of rcc (tumor multifocality, grade and stage) 
might be more important than margin status 
on the development of local recurrence.30 The 
same conclusions were reached by Saito et al. 
in their large retrospective survey on 1193 pa-
tients with malignant rcc treated with SPN, 
where they showed a PSM rate of 2% and a 
local recurrence rate in patients with PSM of 
4%. as such, in their cohort the tumor recur-
rences occurred primarily as metastases (with 
or without local recurrence) and surgical mar-
gin status appeared to have little impact on 
oncological outcomes.31 interestingly, even if 
not included in the quantitative analysis, in the 
study by Kopp et al. on the survival outcomes 
after SPN for clinical T2 renal tumors, there 
were only 2/89 (2.2%) PSMs. in this series, 
the 5-year progression-free survival (PfS), 
cancer-specific survival (cSS) and overall sur-
vival (oS) after SPN were 79.9%, 86.7% and 
83.3%, respectively.32
PSM rate in the Se cohort according to our 
review ranged from 0% to 4% (Table ii). in 
particular, in a large retrospective multicenter 
study by Minervini et al. comparing the onco-
logic outcomes of Se and SPN, PSM rate after 
Se was 1/537 (0.2%) with 1 patient developing 
local recurrence at a median follow-up of 54 
months.33 These findings have been distinctly 
confirmed by three high-quality, well-designed 
studies that are excluded from our meta-anal-
ysis due to a follow-up period shorter than 24 
months 34, 35 or lack of details on the anatomi-
cal sites of local recurrence.36
indeed, Mukkamala et al. reported a PSM 
rate of 3% after Se — with 3 (4%) cases de-
veloping local recurrence at a median follow-
up of 36 months — compared to a PSM rate 
of 7% and a local recurrence rate of 4% in the 
cohort of patients undergoing SPN.36 in their 
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Minervini et al., included in our analysis, the 
PSM rate was 0.2% after Se and 0.5% after 
SPN.31 This findings are confirmed by the ret-
rospective study conducted by Mukkamala et 
al. that, although not included in our review 
for quantitative analysis, reported a slightly 
lower rate of PSM after Se compared to SPN 
(3 vs. 7%32). in light of the peculiar anatomical 
characteristics of the kidney tumor-parenchy-
mal interface 23, 24 and the constant presence of 
prevalence of PSMs among patients undergo-
ing SPN compared to those undergoing Se, as 
clearly evidenced by the overlapping of the 
95% confident intervals (figure 5).14-63
although the ranges clearly differed be-
tween Se and SPN, the pooled estimated prev-
alence of PSM were comparable between the 
two groups in our meta-analysis, highlighting 
that Se is at least non inferior to traditional 
SPN in terms of margin status. in the study by 
figure 5.—forest plot of the crude and pooled prevalences of positive surgical margin among the studies on standard partial 
nephrectomy and simple enucleation included in the review.
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in order to obtain a balanced, evidence-based 
interpretation of the current studies.
The oncologic safety of Se has been demon-
strated by multiple retrospective and prospec-
tive studies showing that the surgical margin 
width was not associated with the oncological 
prognosis.42-44 Moreover, several reports have 
confirmed acceptable oncologic results of Se 
and some have demonstrated similar local 
recurrence-free survival and cancer specific 
survival rates between Se and SPN. one study 
also confirmed similar cancer specific survival 
rates between Se and radical nephrectomy.19
in this context we performed a systematic 
analysis on the rate of local recurrence after 
Se and SPN with a special emphasis on the 
recurrence pattern and location. as previous-
ly explained, lrr has been defined as local 
recurrence in the ipsilateral retroperitoneum, 
while rer as recurrence in the ipsilateral 
kidney (with or without mention of the pos-
sible involvement of the resection bed). The 
need to perform a systematic analysis on the 
recurrence rate after Se and SPN separately 
for lrr and rer is based on the hypothesis 
that such entities include diseases with specific 
pathophysiologic risks (i.e. lymphovascular 
invasion for retroperitoneal lymph node in-
volvement vs. residual tumor growth for recur-
rences at the surgical site of resection).
according to our analysis, among the stud-
ies grouped in the SPN group the prevalence 
of lrr varied from 0% to 9% (Table i). in se-
ries including patients with pT1a or pT1b renal 
masses, the lrr was as low as 0-4%.30, 31, 47, 48
of note, the study by Bigot et al. reporting 
a recurrence rate of 9% at a median follow-up 
of 30 months included only patients with pT2 
or pT3 renal tumors.45 However, the study by 
Kopp et al. showed that the survival outcomes 
of SPN for cT2 renal masses were comparable 
to those of radical nephrectomy (rN) after 
controlling for r.e.N.a.l. nephrometry score 
(5-year PfS and cSS of 69.8% vs. 79.9% 
(P=0.115) and 82.5% vs. 86.7% for PN and 
rN, respectively).32 Moreover, using a large 
national cancer database, alanee et al. showed 
no difference in recurrence rate between PN 
and rN in patients with cT2 renal tumors con-
a microscopic layer of tissue after Se,12 a pos-
sible technical explanation of the lower rate of 
PSM after Se in some recent series 33, 36 might 
be that during Se the surgeon “keeps always 
an eye” on the tumor margin avoiding entry 
into the tumor.37 an alternative explanation 
includes that larger, more infiltrative tumors 
are less amenable to Se and therefore harder 
to achieve a NSM.
overall, the available evidence supports the 
non-inferiority of Se compared to SPN with 
regards to PSMs rate after PN and the potential 
benefits of the enucleative technique in well-se-
lected patients. However, due to the retrospec-
tive and hypothesis-forming nature of most 
series and the lack of standardized reporting of 
rTs in PN literature, no definitive conclusions 
can be drawn to date on the oncological advan-
tage of a specific rT over the others. What is 
shown in our review and meta-analysis is that, 
in the absence of well-controlled randomized 
trials, Se does not compromise oncological 
outcomes after PN and may actually provide 
technical, functional and oncological benefits 
in selected patients.
Prevalence of local recurrence after SPN and 
SE
local recurrence rates after PN have been 
shown to be less than 5% and equivalent to 
those of radical nephrectomy.19, 38 Tradition-
ally, causes of local recurrence include incom-
plete removal of the tumor, multifocality or 
new tumor formation in areas different from 
the resection bed. Whether or not a PSM is a 
risk factor for disease recurrence after PN has 
been controversial;26, 27 however, the current 
view is that patients with PSMs harbor an in-
creased risk of disease recurrence (especially 
in highly malignant tumors) but do not seem to 
influence overall survival and cancer-specific 
survival.39-41 To this regard, an accurate evalu-
ation of the impact of PSMs on the develop-
ment of local recurrence after PN requires a 
careful assessment of tumor features (includ-
ing tumor histotype, stage and complexity), 
resection technique and quality of histopatho-
logical reporting (i.e. exclusion of false PSM) 
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a random effect meta-analysis on the preva-
lence of lrr among the SPN and Se groups 
in studies with a minimum follow-up of 24 
months, the pooled prevalence of LRR was not 
significantly different between the two groups 
(figure 6),14-64 as there was an evident overlap 
of the confidence interval in the pooled estima-
tions between the two groups. in particular, the 
cluding that PN has no detrimental effect on 
cSS.46
The prevalence of lrr in the Se group var-
ied from 0% to 4%. a recent prospective study 
on 304 patients evaluating the prognostic effect 
of capsule penetration on local recurrence after 
Se reported a crude lrr of nearly 1% at a me-
dian follow-up of 52 months.23 By conducting 
figure 6.—forest plot of the crude and pooled prevalences of loco-regional recurrence among the studies on standard partial 
nephrectomy and simple enucleation included in the review.
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after PN that is comparable with that of recent 
reports on this topic.1, 26 in this regard, it is 
important to highlight that the recurrence rate 
range after SPN was reduced when perform-
ing the analysis on rer instead of lrr (0-4% 
vs. 0-9%), becoming comparable to that of Se 
(0-4%, unvaried between the analyses on lrr 
and rer (figures 6, 7). This findings is con-
firmed by the reduction of the pooled preva-
lences of recurrence after SPN when consider-
ing the rer rate compared to those on lrr 
(pooled prevalences of 2.0% and 1.3%, respec-
tively, figures 6, 7). Despite the limited num-
ber of studies included in our meta-analysis on 
rer, the reduced pooled prevalence of recur-
rence in the SPN group may be explained by a 
pooled prevalence of lrr was 2.0% (95% ci: 
1.4-2.8%, tau²=0.48, i2=71.9%, P<0.001) and 
0.9% (95% ci: 0.5-1,7%, tau²=0-48, i2=6-9%, 
P=0.04 for the SPN and Se groups, respec-
tively).
finally, in the sensitivity analysis on renal 
recurrence, performed separately for those 
studies defining the exact anatomical loca-
tion of recurrence, the prevalence of recur-
rence was 1.5% (95% ci: 0.9-2.3%, tau²=0-04 
i2=67.9%, P=0.001) and 0.9% (95% ci: 0.5-
1.7%, tau²=0.04 i2=6.9%, P=0.40) for the SPN 
and Se groups, respectively (figure 7).16-64
overall, these findings offer the opportunity 
for further considerations. first, our results 
confirmed a low rate of both lrr and rer 
figure 7.—forest plot of the crude and pooled prevalences of renal recurrence among the studies on standard partial nephrec-
tomy and simple enucleation included in the review.
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reporting model stressed the importance of 
classifying even the preoperative intent of the 
surgeon into anatomic vs. nonanatomic rSs 
in addition to the SiB Margin score, as a key 
feature to characterize the intent of tumor exci-
sion during PN.8
only one randomized trial was included in 
our final analysis.16 in this regard, although 
randomized controlled trials comparing Se 
and SPN may overcome the limitations of the 
current NSS literature, it is difficult to design 
such trials, as a standardized assessment of the 
rT can only be done a posteriori after surgery 
and not by randomization.8, 50
The definition of PSM is rarely reported 
within the published series. The lack of defini-
tion inherently hinders a meaningful compari-
son of different surgical series, as the possibil-
ity of false PSM (i.e. accidental violation of the 
tumor once it is removed from the surgical field 
or violation of the peritumoral pseudocapsule 
without leaving any malignant tissue in the re-
section bed) is almost never taken into consid-
eration and therefore it might represent a bio-
logically irrelevant bias when interpreting the 
study results. Moreover, there are no accepted 
definitions of local recurrence after PN in the 
current urologic literature. as such, the defini-
tion of lrr used for this review was based on 
the latest eaU guidelines on rcc, but still it 
may not fully represent the spectrum of local 
recurrences after PN. indeed, a hotly debated 
questions within the urological community is 
whether a specific rT is or is not associated 
with an increased risk of PSM and/or local re-
currence. in order to answer this question, an 
objective and shared definition of the surgical-
site renal recurrence (SSr) is necessary. The 
lack of a shared definitions of lrr and rer 
within the PN literature limited the number of 
studies included in the quantitative analysis of 
recurrence rates and therefore the generaliz-
ability of the review results. indeed, only 15 
studies reported in details the exact anatomical 
site of local recurrence within the kidney and 
only two of these explicitly defined whether 
the renal recurrence occurred in the surgical 
resection bed (SSr) or elsewhere in the kidney 
(rer).17, 48 of note, SSr and rer may theo-
trend toward a homogenization of the patient 
population, mainly in terms of pT stage, across 
the studies reporting details on rer. at the 
same time, the pooled prevalences of recur-
rence after Se remained unchanged between 
the analyses on lrr and rer (0.9% each, 
figures 6, 7), confirming a more homogeneous 
patient population in this group.
in light of the previous results on the PSM 
rate, our meta-analysis confirms the non-infe-
riority of Se compared to SPN regarding the 
rate of both lrr and rer. This finding re-
flects the non-inferiority of Se compared to 
SPN with regard to PSM rate, reiterating the 
potential benefits of this technique 8.
Limitations and research needs of the study
The studies included in this review have 
several limitations including inhomogeneity 
with regard to study design, quality of report-
ing and standardization of surgical approach. 
a relevant limitation of our study is that the 
quantitative analysis on the oncological out-
comes after Se included series performed 
predominantly at a single institution.17, 22, 33, 49 
This might theoretically raise concerns regard-
ing the external validity and generalizability of 
the Se results in other patients cohorts. While 
our systematic review did identify other high-
quality, well-designed studies reporting onco-
logical results of Se, they were excluded from 
the quantitative analysis due to the limited 
(<24 months) length of follow-up.34, 35
Most studies included in our review are 
retrospective and did not define either stan-
dardized selection criteria for the choice of a 
specific rT nor the preoperative intent of the 
surgeon (resection strategy, rS). in this regard, 
the Surface-intermediate-Base (SiB) Margin 
score has been proposed as a standardized re-
porting system of rTs during nephron-sparing 
surgery and was validated from a histopatho-
logical perspective showing that the visual 
definitions of rTs used to calculate the score 
are significantly associated with the thickness 
of healthy renal tissue beyond the peritumoral 
pseudocapsule at histopathological analy-
sis.9, 12 of note, an updated comprehensive 
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